negative-space-woman-in-yellow-field-at-sunset - copy
BUILDING THE FOUNDATION

FOR PERSONALIZED MEDICINE AND
BETTER PATIENT OUTCOMES

neagtive-space-woman-in-yellow-field-at-sunset - copy
FOR MINIMALLY INVASIVE
CANCER DIAGNOSTICS
and Infectious Disease
ADVANCING SOLUTIONS
previous arrow
next arrow

Our Cancer Products

  Velox™

World class cancer assay diagnostic test that tags and monitors CTCs.

Magno-Praxis

An immunomagnetic hypothermia treatment to eradicate blood-born cancer cells.

Admonitrix

An innovative medical device that monitors circulating tumor cells in real-time.

IVDiagnostics Team

World-Class Researchers
IVDiagnostics discovers innovative and unique methods that monitor and detect critical cancer cells known as circulating tumor cells (ctc).

Executive Excellence
A strategic leadership team with international experience in healthcare, diagnostics, and therapeutics.

Broad Medical Expertise
Renowned clinicians and physicians with experience in radiology, pathology, hematology, and oncology.

P1100425

WHAT THE EXPERTS ARE SAYING

“We appreciate that there are many different therapies for cancer, and successful treatments will depend on a better understanding of circulating tumor cells that can cause metastases. We believe that IVDiagnostics has the platform technology to rapidly detect and monitor these cells to inform therapeutic approaches.”

MARY J.C. HENDRIX

President & Chief Scientific Officer,
Stanley Manne Children's Research Institute

 "I believe there is a great need for earlier detection and monitoring of patient's circulating tumor cells. The cancer assays from IVDiagnostics have that potential. CLIA laboratories can utilize the Velox product and better serve oncologists with vital and more precise diagnostic data for their  patients."

SAM TERESE

President & CEO,
PCL Alverno

“At Roger Williams we do a significant number of procedures to remove solid tumors. It would be most useful if we had a cancer assay that could monitor reduction or recurrence of circulating tumor cell; given the limitations of what can be observed with present day CT scans and imaging.”

P. SOMASUNDAR MD, MPH, FACS

Associate Chief, Surgical Oncology,
Roger Williams Medical Center